This S&P 500 stock could surge 55% in just 12 months, according to experts

Since joining the S&P 500 in July 2021, Moderna (NASDAQ: MRNA) stock has crashed by 92%. I think that counts as disastrous!

As a shareholder since 2022, I’m down nearly 80% on this position, including 67% in just the past year.

Recently then, I’ve been taking a cold, hard look at Moderna. If I cannot find reasons for optimism, I’ll sell up, take my loss on the chin, and move on. Here’s what I’ve found.

Why, why, why?

As many will remember, Moderna made its name during the pandemic when its mRNA vaccine was fast-tracked for use globally. The biotech firm went from just $35m in revenue in 2018 to over $19bn in 2022. All from a single product.

This year, though, Moderna is forecasting just $1.5bn to $2.2bn in revenue — and a steep loss — as it grapples with declining Covid vaccine sales. Some may say this was bound to happen as the pandemic faded, making my investment foolish.

So, why did I even buy the stock? Well, it related to pattern recognition. Some of my best investments have been made when the market underestimates a company’s potential to become something much more valuable.

Here are three examples from my portfolio:

Stock	How it appeared	The potential I saw	1-year return
Axon Enterprise	Just a Taser and body-cam company	A software-as-a-service powerhouse	176%
Uber	Ride-hailing app at risk of disruption by Tesla	A potential super-app most robotaxis will run on	49%
Games Workshop	Niche retailer for wargame hobbyists	An IP-rich business with global growth opportunities	56%

With Moderna, the market saw a one-trick pony with its Covid vaccine. I saw an mRNA technology platform that was potentially applicable to a wide range of diseases, including various cancers.

Since mRNA is an information-based platform, it works similar to a computerâs operating system, letting researchers insert new genetic code from a virus â like adding an app â to create a new vaccine quickly.

Moderna CEO StÃ©phane Bancel

Q2 update

Obviously, the only recognised pattern here has been a sliding share price. In hindsight, this makes my theory look silly.

Or does it? Because in its Q2 update, Moderna confirmed it’s still targeting another eight product approvals by 2028.

The most exciting candidates are in oncology, where it has Phase 2 and 3 trials across several cancer types, including adjuvant melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma.Â

Meanwhile, the firm’s flu vaccine recently delivered positive late-stage results, paving the way for a Covidâflu combination vaccine.

Brokers forecast sales bottoming out this year. They then see revenue rising 20% next year to $2.3bn, followed by a further 25% jump to $2.9bn in 2027. Piper Sandler is more bullish, anticipating $4.3bn in sales by 2027 (more than double this year’s).

The biggest risk is that Moderna remains loss-making due to falling Covid sales and heavy investments in its late-stage pipeline. If its cancer vaccines ultimately disappoint, that would be a major setback.

However, the company still had $7.5bn in cash/equivalents last month. And due to cost-cutting, management says it’s on course to break even on a cash-cost basis by 2028.

My move

Weighing things up, I reckon more patience is required. So I’m going to keep holding (and praying).

Another glimmer of hope is that Wall Street’s price target of $42.85 is 55% higher than today’s level. Naturally, Moderna might never reach this, but it would be a nice boost.

Potential investors should know this is a high-risk, high-reward stock. It could generate fabulous returns from here, or flop further.

The post This S&P 500 stock could surge 55% in just 12 months, according to experts appeared first on The Motley Fool UK.

More reading

Ben McPoland has positions in Axon Enterprise, Games Workshop Group Plc, Moderna, and Uber Technologies. The Motley Fool UK has recommended Axon Enterprise, Games Workshop Group Plc, Moderna, Tesla, and Uber Technologies. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.